Eosinophilic Esophagitis - Pipeline Review, H1 2018

  • ID: 4515996
  • Report
  • 63 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Adare Pharmaceuticals Inc
  • Banner Life Sciences LLC
  • Calypso Biotech SA
  • Celgene Corp
  • DBV Technologies SA
  • Quorum Innovations LLC
  • MORE
Eosinophilic Esophagitis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Eosinophilic Esophagitis - Pipeline Review, H1 2018, provides an overview of the Eosinophilic Esophagitis (Gastrointestinal) pipeline landscape.

Eosinophilic esophagitis is disease characterized by the presence of a large number of a special type of white blood cell, the eosinophil that can cause inflammation in the esophagus. Symptoms include poor weight gain, abdominal pain, nausea, and vomiting, coughing, heartburn and chest pain. Risk factors include weakened immune system, chemotherapy, aspirin and anti-inflammatory medications, chronic vomiting, obesity and alcohol and cigarette use. Treatment includes antiviral, antifungal and pain relievers.

Report Highlights:

This latest Pharmaceutical and Healthcare disease pipeline guide pipeline guide Eosinophilic Esophagitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Eosinophilic Esophagitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Eosinophilic Esophagitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 4, 3 and 1 respectively.

Eosinophilic Esophagitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researechers' proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Eosinophilic Esophagitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Eosinophilic Esophagitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Eosinophilic Esophagitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Eosinophilic Esophagitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Eosinophilic Esophagitis (Gastrointestinal)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Eosinophilic Esophagitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Adare Pharmaceuticals Inc
  • Banner Life Sciences LLC
  • Calypso Biotech SA
  • Celgene Corp
  • DBV Technologies SA
  • Quorum Innovations LLC
  • MORE
Introduction

Report Coverage

Eosinophilic Esophagitis - Overview

Eosinophilic Esophagitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Eosinophilic Esophagitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Eosinophilic Esophagitis - Companies Involved in Therapeutics Development

Adare Pharmaceuticals Inc

Banner Life Sciences LLC

Biotica Pharmaceuticals Inc

Calypso Biotech SA

Celgene Corp

DBV Technologies SA

Quorum Innovations LLC

Regeneron Pharmaceuticals Inc

Shire Plc

Eosinophilic Esophagitis - Drug Profiles

BPRX-060216 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

budesonide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CALY-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dupilumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fluticasone propionate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fluticasone propionate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Qi-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RPC-4046 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Viaskin Milk - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Eosinophilic Esophagitis - Dormant Projects

Eosinophilic Esophagitis - Product Development Milestones

Featured News & Press Releases

Oct 16, 2017: Sanofi and Regeneron Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis

Feb 03, 2017: DBV Technologies Announces Completion of Enrollment of Phase IIA Study of Viaskin Milk for the Treatment of Pediatric Eosinophilic Esophagitis

Oct 13, 2016: Celgene to Present New Data on RPC4046 at UEGW and ACG Congresses

Sep 21, 2016: DBV Technologies Receives FDA Fast Track Designation for Viaskin Milk for the Treatment of Cows Milk Protein Allergy

Jun 13, 2016: Shire Receives FDA Breakthrough Therapy Designation for Investigational Product SHP621 for Rare Gastrointestinal Conditions

Nov 12, 2015: DBV Technologies Announces Enrollment of First Patient in Phase IIA Study in Pediatric Eosinophilic Esophagitis

Jul 08, 2015: IND Acceptance from FDA for a proof-of-concept trial using Viaskin® Milk in Milk-Induced Eosinophilic Esophagitis in Children

Oct 03, 2014: Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis

Sep 25, 2014: Meritage Pharma Announces Positive Results of Oral Budesonide Suspension for Treatment of Eosinophilic Esophagitis in Adolescent and Adult Patients

Jul 21, 2014: High-dose fluticasone effective against eosinophilic esophagitis

May 13, 2014: DBV Technologies Announces Clinical Trial Agreement to Develop a Treatment for Milk-Induced Eosinophilic Esophagitis in Children

Aug 13, 2012: Meritage Initiates Clinical Trial Of Oral Budesonide Suspension For Adolescent And Adult Patients With Eosinophilic Esophagitis

May 10, 2011: Meritage Pharma Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis

May 10, 2011: Meritage Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Eosinophilic Esophagitis, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Eosinophilic Esophagitis - Pipeline by Adare Pharmaceuticals Inc, H1 2018

Eosinophilic Esophagitis - Pipeline by Banner Life Sciences LLC, H1 2018

Eosinophilic Esophagitis - Pipeline by Biotica Pharmaceuticals Inc, H1 2018

Eosinophilic Esophagitis - Pipeline by Calypso Biotech SA, H1 2018

Eosinophilic Esophagitis - Pipeline by Celgene Corp, H1 2018

Eosinophilic Esophagitis - Pipeline by DBV Technologies SA, H1 2018

Eosinophilic Esophagitis - Pipeline by Quorum Innovations LLC, H1 2018

Eosinophilic Esophagitis - Pipeline by Regeneron Pharmaceuticals Inc, H1 2018

Eosinophilic Esophagitis - Pipeline by Shire Plc, H1 2018

Eosinophilic Esophagitis - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Eosinophilic Esophagitis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Adare Pharmaceuticals Inc
  • Banner Life Sciences LLC
  • Biotica Pharmaceuticals Inc
  • Calypso Biotech SA
  • Celgene Corp
  • DBV Technologies SA
  • Quorum Innovations LLC
  • Regeneron Pharmaceuticals Inc
  • Shire Plc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll